HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pituitary cachexia — Clinical Guidelines

Overview

Cachexia is a systemic wasting condition characterized by significant weight loss, muscle atrophy, and decreased quality of life, often seen as a late complication of diseases such as cancer, organ failure, and infections 1. It contributes substantially to morbidity and mortality but its underlying mechanisms are not fully elucidated 1.

Diagnosis

Clinical Criteria: Weight loss, muscle wasting, anorexia, and fatigue 1.

Laboratory Tests: Elevated inflammatory markers (e.g., IL-6, TNF) may be indicative 1 7.

Imaging and Biomarkers: Multi-organ damage assessment via imaging and biomarkers like DNA instability and lipid peroxidation can support diagnosis 7.

Staging Systems: Utilize precachexia, cachexia, and refractory cachexia staging proposed by expert panels 5.

Management

First-Line Treatments:

- Nutritional Support: Parenteral nutrition may be considered in advanced cases, though evidence varies 3. - Anti-inflammatory Agents: Limited evidence supports use in specific contexts 1 7.

Adjunctive Treatments:

- Opioid Rotation: Avoid transdermal fentanyl in cachexia; switch to parenteral routes cautiously, adjusting doses carefully 2 4. - Geriatric Considerations: Use anticachexic medications cautiously due to safety concerns in elderly patients 6.

Special Populations

Elderly: Anticachexic medications should be used with caution due to potential safety risks 6.

Cancer Patients: Specific attention to pain management, avoiding transdermal fentanyl when possible 2 4.

Key Recommendations

Avoid transdermal fentanyl in patients with cachexia due to potential absorption issues and risk of overdose; switch to parenteral opioids with careful dose adjustment 2 4 (Evidence: Moderate).

Utilize staging systems like precachexia, cachexia, and refractory cachexia for better clinical management and communication 5 (Evidence: Expert opinion).

Consider parenteral nutrition in advanced cancer cachexia cases, though evidence is mixed 3 (Evidence: Weak).

References

1 Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ et al.. Cachexia: A systemic consequence of progressive, unresolved disease. Cell 2023. link 2 Alsirafy SA, Alabdullateef SH, Elyamany AM, Hassan AD, Almashiakhi M. Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia. BMJ supportive & palliative care 2022. link 3 Bozzetti F. Supplemental Parenteral Nutrition in Patients with Cancer. The oncologist 2021. link 4 Lam D, Kay S, Pickard J, Harrison S. Unusual case of transdermal fentanyl in cachexia. BMJ supportive & palliative care 2019. link 5 MacDonald N. Terminology in cancer cachexia: importance and status. Current opinion in clinical nutrition and metabolic care 2012. link 6 Yeh SS, Lovitt S, Schuster MW. Pharmacological treatment of geriatric cachexia: evidence and safety in perspective. Journal of the American Medical Directors Association 2007. link 7 Noriki S, Imamura Y, Ikeda T, Nakanishi K, Miyoshi N, Kohno M et al.. Multi-organ damage (MOD) induced by cancer cachexia and its pathogenesis. Basic and applied histochemistry 1989. link 8 Price SR, Olivecrona T, Pekala PH. Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor--the primary regulatory role of the hormone in 3T3-L1 adipocytes. Archives of biochemistry and biophysics 1986. link90384-x)

Pituitary cachexia